Therapeutics News and Research

RSS

Innovative delivery systems and methods to treat breast cancer

In their lifetime, women have more than a 12 percent risk of being diagnosed with breast cancer. 1 This week, research on novel approaches to breast cancer treatment is being presented at the Era of Hope (EOH) conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program (BCRP).

4 Aug 2011

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a patent in France and the United Kingdom relating to the treatment and detection of multiple myeloma and ovarian cancer.

4 Aug 2011

Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation today announced that the companies have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia.

3 Aug 2011

SuperGen second quarter net income decreases to $903,000

SuperGen, Inc. today reported financial results for the second quarter ended June 30, 2011. The Company reported net income for the 2011 second quarter of $903,000, or $0.01 per basic and diluted share, compared with $961,000, or $0.02 per basic and diluted share, for the same prior year period.

3 Aug 2011

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

Zalicus second quarter revenue decreases to $1.8 million

Zalicus Inc. today reported financial results for the second quarter ended June 30, 2011.

3 Aug 2011

New approach to overcome complexities of developing more effective drugs for treating diseases

Pharmaceutical scientists typically face a meager five percent success rate for anti-cancer drugs in clinical trials. To help improve this success rate, Japanese scientists, led by Dr. Tetsuya Terasaki, one of the top pharmaceutical scientists focused on drug transporters, have developed a new approach designed to overcome complexities of developing new, more effective drugs to treat diseases, including cancer.

3 Aug 2011

Federal appeals court partially reverses ruling in BRCA patents case

In a 2-1 decision, a federal appeals court today partially reversed a lower court's ruling in a case challenging patents on two human genes, BRCA1 and BRCA2, associated with hereditary breast and ovarian cancer. The court ruled that companies can obtain patents on the genes but cannot patent methods to compare those gene sequences.

3 Aug 2011

MSMB offers $18 per share for Amag acquisition

MSMB Capital Management today announced that it has made a proposal to the Board of Directors of Amag Pharmaceuticals Inc. to acquire all of the outstanding shares of common stock of Amag for $18 per share in cash or an aggregate of $378 million.

3 Aug 2011

Akorn enters agreement to acquire minority ownership in Aciex

Akorn, Inc., a niche specialty pharmaceutical company, today announced that it has entered into an agreement to acquire a minority ownership in Westborough, MA, based Aciex Therapeutics Inc., an ophthalmic drug development company with a focus on developing novel therapeutics to treat ocular diseases.

3 Aug 2011

GSK, NPS enter agreement to evaluate ronacaleret in new indications

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported that it has entered into a new agreement with GlaxoSmithKline (GSK), that terminates and replaces a prior collaborative research and license agreement between NPS and GSK from 1993, which focused on the discovery and development of small molecule antagonists of the calcium receptor that increase secretion of parathyroid hormone.

3 Aug 2011

Lipid nanocarriers in cancer diagnosis and therapy: New book

This book introduces fundamental principles of lipid nanocarriers science relevant to cancer therapy. The first in this field, it fills a need for an accurate, coherent and authoritative introduction to lipid nanocarriers focusing in cancer therapy; both because of the growing popularity of these modern drug delivery systems and also because of the emergent need of dealing with cancer treatment.

2 Aug 2011

BARDA awards contracts for development of drugs for radiation injury to the GI tract

The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

2 Aug 2011

Akorn second quarter revenue grows 59% to $32.1 million

Akorn, Inc., a niche specialty pharmaceutical company, today reported financial results for the second quarter of 2011. The Company also separately announced that it has entered into an agreement to acquire a minority ownership in Westborough, MA, based Aciex Therapeutics Inc., an ophthalmic drug development company with a focus on developing novel therapeutics to treat front-of-eye diseases.

2 Aug 2011

One in six older people likely to have abnormal liver test and die from all causes

One in six people over 75 are likely to have at least one abnormal liver test and those that have two or more are twice as likely to die from cancer and 17 times more likely to die from liver disease, according to research in the August issue of Alimentary Pharmacology and Therapeutics.

2 Aug 2011

Lack of TLR1 surface expression linked with increased susceptibility to tuberculosis

Are you genetically predisposed to tuberculosis? Scientists may now be able to answer this question and doctors may be able to adjust their therapeutic approach based on what they learn. That's because new research presented in the Journal of Leukocyte Biology suggests that two frequent mutations in an immune system gene called TLR1 are responsible for cellular changes that ultimately make us less likely to resist the disease.

2 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

HT, B.Braun partner to launch Adenocaine Hiberplegia syringe pump delivery system

Hibernation Therapeutics USA, LLC has partnered with B. Braun Medical Inc. to introduce an innovative, low-cost syringe pump delivery system for the administration of its patented Adenocaine Hiberplegia solution, the world's first non-depolarizing cardioplegia.

From B. Braun Melsungen AG 1 Aug 2011

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

1 Aug 2011

RegenoCELL to open new facility in Panama for treatment of congestive heart failure

RegenoCELL Therapeutics, Inc., a leader in adult stem cell therapy, is pleased to announce it is planning to open another state of the art facility in Panama for patients to be treated for congestive heart failure and peripheral artery disease with its autologous stem cell therapy.

30 Jul 2011

Therapeutics News and Research

Innovative delivery systems and methods to treat breast cancer

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia

SuperGen second quarter net income decreases to $903,000

Celldex second quarter net loss increases to $10.2 million

Zalicus second quarter revenue decreases to $1.8 million

New approach to overcome complexities of developing more effective drugs for treating diseases

Federal appeals court partially reverses ruling in BRCA patents case

MSMB offers $18 per share for Amag acquisition

Akorn enters agreement to acquire minority ownership in Aciex

GSK, NPS enter agreement to evaluate ronacaleret in new indications

Lipid nanocarriers in cancer diagnosis and therapy: New book

BARDA awards contracts for development of drugs for radiation injury to the GI tract

Akorn second quarter revenue grows 59% to $32.1 million

One in six older people likely to have abnormal liver test and die from all causes

Lack of TLR1 surface expression linked with increased susceptibility to tuberculosis

Alnylam second quarter revenue decreases to $20.6 million

HT, B.Braun partner to launch Adenocaine Hiberplegia syringe pump delivery system

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

RegenoCELL to open new facility in Panama for treatment of congestive heart failure

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News